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Background: Anthroposophic treatment for chronic low back pain (LBP) includes special 
artistic and physical therapies and special medications. In a previously published prospective 
cohort study, anthroposophic treatment for chronic LBP was associated with improvements of 
pain, back function, and quality of life at 12-month follow-up. These improvements were at least 
comparable to improvements in a control group receiving conventional care. We conducted a 
two-year follow-up analysis of the anthroposophic therapy group with a larger sample size.
Methods: Seventy-five consecutive adult outpatients in Germany, starting anthroposophic 
treatment for discogenic or non-specific LBP of 6 weeks’ duration participated in a 
prospective cohort study. Main outcomes were Hanover Functional Ability Questionnaire 
(HFAQ; 0–100), LBP Rating Scale Pain Score (LBPRS; 0–100), Symptom Score (0–10), and 
SF-36 after 24 months.
Results: Eighty-five percent of patients were women. Mean age was 49.0 years. From baseline 
to 24-month follow-up all outcomes improved significantly; average improvements were: 
HFAQ 11.1 points (95% confidence interval [CI]: 5.5–16.6; p  0.001), LBPRS 8.7 (95% 
CI: 4.4–13.0; p  0.001), Symptom Score 2.0 (95% CI: 1.3–2.8; p  0.001), SF-36 Physical 
Component Summary 6.0 (95% CI: 2.9–9.1; p  0.001), and SF-36 Mental Component 
Summary 4.0 (95% CI: 1.1–6.8; p = 0.007).
Conclusion: Patients with chronic LBP receiving anthroposophic treatment had sustained 
improvements of symptoms, back function, and quality of life, suggesting that larger multicenter 
rigorous studies may be worthwhile.
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Background
Low back pain (LBP) affects 50%–80% of adults at some point in life1 and is a 
frequent cause of disability, sick-leave, and health service use.2 At least 10% of 
patients with acute LBP do not improve within four weeks, and 42%–75% are not 
fully recovered within 12 months.3 Standard conventional treatment of chronic LBP 
is often unsatisfactory.2
One complementary therapy used for LBP is anthroposophic medicine (AM). 
AM acknowledges a spiritual–existential dimension in man, which is assumed to 
interact with psychological and somatic levels in health and disease. AM therapy for 
chronic LBP aims to counteract constitutional vulnerability, stimulate salutogenetic 
self-healing capacities, and strengthen patient autonomy.4,5 This is sought to be achieved 
by counseling, by nonverbal therapies such as AM eurythmy therapy, rhythmical 
massage therapy, art therapy, and by special AM medications.4Journal of Pain Research 2009:2 76
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Eurythmy therapy (Greek: eurythmy, “harmonious 
rhythm”, is an artistic exercise therapy involving cognitive, 
emotional, and volitional elements.6 In eurythmy therapy 
sessions the patients exercise specific movements with the 
hands, the feet, or the whole body. Eurythmy movements 
are related to the sounds of vowels and consonants, to music 
intervals or to soul gestures, eg, sympathy-antipathy. Between 
therapy sessions the patients exercise eurythmy movements 
daily.4 Rhythmical massage therapy was developed from 
Swedish massage; special techniques include lifting 
movements, rhythmically undulating gliding movements, 
and complex movement patterns like lemniscates. In AM 
art therapy the patients engage in painting, drawing, clay 
modeling, music or speech exercises. AM medications are 
prepared from plants, minerals, animals, and from chemically 
defined substances. A key concept of AM medication therapy 
is typological correspondences between pathophysiological 
processes in man and formative forces working in minerals, 
plants, and animals, reflecting a common evolution of man 
and nature.4,5
AM therapy is provided by physicians (counseling, 
AM medication) and nonmedical therapists (eurythmy, 
rhythmical massage, art). For patients with chronic LBP 
the physician will choose among the available AM therapy 
modalities in order to tailor the treatment to individual needs 
of the patient.
To date AM therapy for LBP has been evaluated in three 
observational studies, conducted in specialized settings.7–9 
We conducted a prospective observational comparative study 
of outpatients treated by AM physicians or conventional 
physicians for subacute/chronic LBP. A previously pub-
lished 12-month analysis comprising 34 AM patients and 
28 conventionally treated patients showed improvements 
of symptoms, back function, and quality of life in both 
groups. Most improvements (10 of 13 clinical outcomes) 
were comparable in the two groups, while the AM patients 
had more outspoken improvements in three quality of 
life domains.10 Study logistics and funding allowed for a 
prolonged recruitment and follow-up of AM patients but not 
of the conventionally treated patients. Here we present an 
analysis of a larger sample of AM patients from this study, 
followed up for two years.
Methods
study design and objective
This is a follow-up analysis of a prospective observational 
comparative cohort study of subacute/chronic LBP in a 
real-world medical setting.10 The LBP study10 was part of 
a larger research project on the effectiveness, costs, and 
safety of AM therapies in outpatients with chronic disease 
(Anthroposophic Medicine Outcomes Study; AMOS).11 
The present follow-up analysis of the LBP study concerned 
the intervention group with patients starting AM therapies 
for LBP. The primary question was if the improvements in 
symptoms, back function, and quality of life observed after 
12 months in a previous analysis10 were confirmed in a larger 
sample and were maintained at two-year follow-up. Further 
research questions concerned the use of adjunctive therapies 
and health services as well as adverse reactions.
setting, participants, and therapy
All physicians certified by the Physicians’ Association for 
Anthroposophical Medicine in Germany and working in 
an office-based practice or worked in outpatient clinics in 
Germany were invited to participate in the AMOS study. The 
participating physicians recruited consecutive outpatients 
starting AM therapy under routine clinical conditions. 
Patients enrolled from January 1st, 1999 to December 31st, 
2005 were included in the present analysis if they fulfilled 
the eligibility criteria.
Inclusion criteria were
1.  Age 17–75 years
2.  LBP of at least six weeks duration
3.  Starting AM therapy for LBP: AM-related consultation of 
at least 30 minutes followed by new prescription of AM 
medication, or new referral to AM therapy (art, eurythmy, 
or rhythmical massage).
Exclusion criteria were:
1.  Previous back surgery.
2.  Any of the following diagnoses: Congenital spinal 
malformation, spinal infectious or malignant disease, 
ankylosing spondylitis, Behçet’s syndrome, Reiter’s 
syndrome, osteoporosis with vertebral fracture, spinal 
stenosis, spondylolysis, spondylolisthesis, or fibromyalgia.
3.  Previous use of the AM therapy in question (see inclusion 
criteria No 3) for LBP.
The patients were treated according to the physician’s 
discretion. AM therapy was evaluated as a whole system.12
clinical outcomes
Primary outcomes were the Hanover Functional Ability 
Questionnaire (HFAQ) and the Low Back Pain Rating Scale 
Pain Score (LBPRS) after 24 months.
The HFAQ (German: Funktionsfragebogen Hannover für 
Rückenschmerzen; FFbH-R) is a self-rating questionnaire 
of back-specific functional disability.13 The HFAQ consists Journal of Pain Research 2009:2 77
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of 12 activity-related questions (eg, “Can you bend down 
to pick up a paper from the floor?”) which are answered on 
three-point Likert scales (“Can do without difficulty”/“Can 
do, but with some difficulty”/“Either unable to do or only 
with help”). The HFAQ score ranges from 0 (minimal 
function) to 100 (optimal function, no limitation); a score 
of 70 points indicates a clinically significant functional 
limitation. The World Health Organization lists the HFAQ 
among the three most relevant disease-specific instruments 
for spinal disorders.14
The LBPRS15 consists of three back pain and three leg 
pain items: current pain, worst pain, and average pain during 
the last seven days, assessed on numerical rating scales from 
0 (“no pain”) to 10 (“unbearable pain”). The LBPRS ranges 
from 0 (6 × “no pain”) to 100 (6 × “unbearable pain”).
Secondary clinical outcomes were Symptom Score, 
depressive symptoms, and quality of life. Symptom Score, 
the severity of one to six most relevant symptoms present 
at baseline, was assessed by patients on numerical rating 
scales from 0 (“not present“) to 10 (“worst possible“). 
Depressive symptoms were assessed with the Center for 
Epidemiological Studies Depression Scale, German version 
(CES-D; 0–60).16,17 Quality of life was assessed with the 
SF-36 Health Survey (Physical and Mental Component 
summary measures, eight scales).18
All clinical outcomes were documented after 0, 3, 6, 12, 
18, and 24 months.
Other outcomes
Use of adjunctive therapies and health services in the pre-study 
year was documented at study entry, use in the first study 
year was documented after six and 12 months, and use in the 
second study year was documented after 18 and 24 months. 
The following items were documented: back-related physician 
visits (visits to general practitioners, internists, orthopedic 
surgeons, neurologists, or psychiatrists), diagnostic imaging 
(X-rays, computer tomography, magnetic resonance 
imaging, scintigrams), non-AM medications, physiotherapy, 
psychotherapy, inpatient hospital and rehabilitation treatment, 
and sick leave. In addition, back-related surgery was 
documented during follow-up.
Adverse reactions to medications or therapies were 
documented by the patients after 6, 12, 18 and 24 months 
and by the physicians after six months. The documentation 
included cause, intensity (mild/moderate/severe = no/some/
complete impairment of normal daily activities), and therapy 
withdrawal because of adverse reactions. Serious adverse 
events (death, life-threatening condition, acute in-patient 
hospitalization, new disease or accident causing permanent 
disability, congenital anomaly, new malignancy) were 
documented by physicians throughout the study.
Data collection
All data were documented with questionnaires returned 
in sealed envelopes to the study office. The physicians 
documented eligibility criteria; the therapists documented 
AM therapy administration; the physicians as well as 
patients documented adverse reactions; all other items were 
documented by the patients, unless otherwise stated. The 
patient responses were not made available to the physicians. 
The physicians were compensated 40 Euro (after March 
2001: 60 Euro) per included and fully documented patient, 
while the patients received no compensation.
The data were entered twice by two different persons 
into Microsoft® Access 97 (Microsoft Corp., Redmond, WA, 
USA). The two datasets were compared and discrepancies 
resolved by checking with the original data.
Quality assurance, adherence  
to regulations
The study was approved by the Ethics Committee of the 
Faculty of Medicine Charité, Humboldt University, Berlin, 
Germany, and was conducted according to the Declaration of 
Helsinki and largely following the ICH Guideline for Good 
Clinical Practice E6. Written informed consent was obtained 
from all patients before enrolment.
Data analysis
The data analysis was performed on all patients fulfilling 
the eligibility criteria, using SPSS® 14.0.1 (SPSS Inc., 
Chicago, IL, USA) and StatXact® 5.0.3 (Cytel Software 
Corporation, Cambridge, MA, USA). T-test was used 
for continuous data with normal distribution; Wilcoxon 
signed-rank test was used for paired continuous data with 
nonnormal distribution; McNemar test and Fisher’s exact test 
were used for dichotomous data. All tests were two-tailed. 
Significance criterion was p  0.05. Since this was a 
descriptive study, no adjustment for multiple comparisons 
was performed.19 Pre-post effect sizes were calculated as 
standardized response mean (SRM; mean change score 
divided by the standard deviation of the change score) and 
classified as minimal (0.20), small (0.20–0.49), medium 
(0.50–0.79), and large (0.80).20,21 Clinical relevance criteria 
for pre-post changes were SRM  0.50.22 In the main analysis, 
outcomes were analyzed in patients with evaluable data for 
each follow-up, without replacement of missing values.Journal of Pain Research 2009:2 78
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Results
Participating physicians and therapists
The patients were enrolled by 33 physicians with four 
different qualifications (27 general practitioners, four 
internists, one psychiatrist, and one anesthesiologist). 
Comparing these physicians to AM-certified physicians 
in Germany with the same four qualifications but without 
study patients (n = 285), no significant differences were 
found regarding gender (57.6% vs. 59.3% males), age (mean 
46.6 ± 7.5 vs. 48.3 ± 8.1 years), number of years in practice 
(18.4 ± 7.8 vs. 19.5 ± 9.2), and the proportion of physicians 
working in primary care (90.9% vs. 87.7%).
The  patients  were  treated  by  41  different  AM 
therapists (art, eurythmy, rhythmical massage). Comparing 
these therapists to certified therapists without study patients 
(n = 1125), no significant differences were found regarding 
gender (87.8% vs. 80.8% females), age (mean 49.9 ± 8.2 vs 
50.3 ± 9.5 years) or the number of years since therapist 
qualification (10.8 ± 7.7 vs. 13.2 ± 8.7 years).
Patient recruitment and follow-up
A total of 103 patients starting AM treatment for LBP 
were screened for inclusion. Of these patients, 75 fulfilled 
all eligibility criteria and were included in the analysis. 
28 patients were not included; 22 of these were not eligible 
for the following reasons: LBP of less than six weeks duration 
(n = 4), previous back surgery (n = 4), or diagnosis listed 
in exclusion criteria (n = 14). The remaining six patients 
were potentially eligible for the present analysis but not 
included in the AMOS study for the following reasons: 
previous or ongoing use of AM therapy in question (n = 2), 
patients’ baseline questionnaire missing (n = 1), patients’ 
and physicians’ baseline questionnaire dated 30 days apart 
(n = 2), or physician’s baseline questionnaire received 2 
months after enrolment (n = 1). Each physician enrolled 1–2 
patients (n = 26 physicians), 3–5 patients (n = 4), or 6–11 
patients (n = 3). A total of 96% (n = 72/75) of patients were 
enrolled by physicians working in primary care.
A total of 88% (n = 66/75) of patients returned at least 
one follow-up questionnaire. The patients were administered 
a total of 375 questionnaires, out of which 289 (77.1%) 
were returned. Follow-up rates were 84% (n = 63/75), 
83%, 80%, 72%, and 67% after 3, 6, 12, 18, and 24 months, 
respectively. Respondents (n = 50) and nonrespondents 
(n = 25) of the 24-month follow-up questionnaire did not 
differ significantly regarding gender, LBP duration, or 
baseline parameters (HFAQ, LBPRS, Symptom Score). 
Mean age was 51.1 ± 11.4 in respondents and 44.9 ± 12.2 in 
nonrespondents (mean difference 6.2 years, 95% confidence 
interval [CI]: 0.5–12.0; p = 0.032).
A dropout survey was performed for AMOS patients 
enrolled for any indication in the last recruitment year (2005) 
who had not returned the 24-month follow-up questionnaire 
(n = 44 of 119 enrolled patients). Of these 44 patients, two 
had died for reasons unrelated to therapy and nine had 
previously refused further study participation. The remaining 
33 patients were contacted by telephone: 10 were unreachable, 
one refused to be interviewed, and 22 patients gave reasons 
for nonresponding: no time or not interested (n = 8), forgotten 
(n = 7), therapy completed (n = 4), disagreement with 
therapist, therapy discontinued (n = 1), never had therapy 
(n = 1), or deterioration of primary disorder (n = 1). The 
proportion of patients with deterioration, including the two 
deaths unrelated to therapy, was 6.8% (n = 3/44) of dropouts. 
The corresponding proportion among patients returning the 
24-month follow-up questionnaire, assessed by a deterioration 
of Symptom Score from baseline after 24 months, was 5.4% 
(n = 4/74) of patients (p = 1.000).
Baseline characteristics
The patients were recruited from 11 of 16 German federal 
states. Age groups were 20–39 years: 18% (n = 18/75), 40–59 
years: 55% (n = 41), 60–75 years: 21% (n = 16) with a mean 
age of 49.0 ± 12.0 years (range 20–74 years). A total of 85% 
(n = 64/75) of the patients were women.
Compared with the German population, patients had higher 
educational and occupational levels and were less frequently 
regular smokers, daily alcohol consumers, and overweight; 
patients were more often living alone, whereas more patients 
engaged in sports than in the population. Sociodemographic 
status was similar to the population regarding unemployment, 
income, and severe disability status and less favorable for 
work disability pension and sick leave (Table 1).
Median LBP duration was 7.0 years (Interquartile 
range [IQR]: 2.5–18.0, mean 10.7 ± 10.6 years). The 
main diagnosis, classified by International Classification 
of Diseases, Tenth Edition (ICD-10), was M54 Dorsalgia 
(55% of patients, n = 41/75), M51 Other intervertebral disc 
disorders (19%), M42 Spinal osteochondrosis (11%), M41 
Scoliosis (9%), M47 Spondylosis (4%), and other (3%). 
One-fourth of patients had lumbar disc disease with nerve 
root compression; half of patients had a clinically relevant 
limitation in back function (Table 1).
A current comorbid disease was present in 79% (67/75) 
of patients, with a median of 2.0 (IQR: 1.0–3.0) comorbid 
diseases per patient. Most common comorbid diseases, Journal of Pain Research 2009:2 79
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classified by ICD-10, were F00–F99 Mental disorders 
(15.6%, 26 of 167 diagnoses), M00–M99 Musculoskeletal 
diseases (15.6%), I00–I99 Cardiovascular disorders (15.0%), 
E00–E90 Endocrine, nutritional and metabolic diseases 
(10.2%), and K00–K93 Digestive system diseases (9.6%). 
One-third of patients had clinically relevant depressive 
symptoms (Table 1).
Therapy
At study enrolment, the duration of the consultation 
with the AM physician was 30 min in 67% (n = 50/75) 
of patients, 30–44 min in 25%, 45–59 min in 5%, and 
60 min in 3% of patients. At enrolment one patient 
started AM medical treatment provided by the physician, 
while the remaining 74 patients were referred to AM 
eurythmy/art/massage therapy. Of these 74 patients, 82% 
(n = 61) had the planned AM therapy, 1% (n = 1) did not 
have AM therapy, and for 16% (n = 12) the AM therapy 
documentation was incomplete. AM therapies used were 
eurythmy therapy (n = 45 patients), rhythmical massage 
therapy (n = 13), and art therapy (n = 3, with the therapy 
modality painting/drawing/clay in all three cases). The 
AM eurythmy/art/massage therapy started median 12 days 
(IQR: 3–38) days after enrolment. Median therapy dura-
tion was 98 days (IQR: 70–146 days), median number of 
therapy sessions was 12 (IQR: 10–12). AM medications 
were used by 69% (52/75) of patients.
The use of adjunctive therapies, health services, and 
sick leave was compared between the pre-study year 
and the first and second years, respectively (see Meth-
ods for details). No items changed significantly in any 
period. Back-related surgery occurred in one patient, 
who had surgery for a coccygeal fistula in the second 
study year.
Table 1 Baseline data of study population
Items Subgroup Study patients German population Source
N % %
education29 Low (level 1 ) 11/75 15% 43% 30
intermediate (level 2) 38/75 51% 43%
High (level 3) 26/75 35% 14%
Wage earners economically active patients 4/38 11% 18% 31
Unemployed during last 12 months economically active patients 4/38 11% 10% 31
Living alone 22/74 30% 21% 31
net family income 900€ per month 11/57 19% 16% 31
Alcohol use daily (patients) vs almost daily (germany) Male 0/11 0% 28% 32
Female 2/64 3% 11%
Regular smoking Male 2/11 18% 37% 33
Female 4/64 6% 28%
sports activity 1 hour weekly Age 25–69 34/71 48% 39% 34
Body mass index 25 (overweight) Male 4/11 36% 56% 31
Female 29/62 45% 39%
Permanent work disability pension 7/74 9% 3% 35
severe disability status 10/74 14% 12% 36
sick leave days in the last 12 months (mean ± sD) economically active patients 38.3 ± 58.0 17.0 37
Low back pain duration 6 weeks–2 months 4 5%
3–5 months 1 1%
6–11 months 3 4%
12 months 67 89%
Lumbar disc herniation or protrusion with nerve root 
compression
17/75 23%
HFAQ  70 points = clinically relevant limitation in 
back function
34/73 47% 22%
38
ces-D  24 points = depressive range 25/67 37% 17% 17
Abbreviations: ces-D, center for epidemiological studies Depression scale, german version;  HFAQ, Hanover Functional   Ability Questionnaire.Journal of Pain Research 2009:2 80
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clinical outcomes
HFAQ, LBPRS, Symptom Score, CES-D, and the ten SF-36 
scores improved significantly between baseline and nearly all 
subsequent follow-ups (66 significant and four nonsignificant 
improvements in 70 pre-post comparisons). For nearly all 
outcomes, the most pronounced improvement occurred 
during the first six months (Figures 1–5). Effect sizes for 
the 0–24-month comparisons were large for two outcomes 
(SF-36 Bodily Pain), medium for seven outcomes, and small 
for six outcomes (Table 2).
Comparing the improvements from baseline to last 
follow-up of the present sample (n = 49 evaluable patients 
after 24 months) to the corresponding improvements of 
the previously published analysis of a smaller sample 
from the same project (n = 34 patients after 12 months,10) 
differences between the two analyses were minimal 
(less than 0.2 standard deviations [SD]) for 11 outcomes 
and small (0.20–0.22 SD) for two outcomes (SF-36 
Role Emotional and SF-36 Bodily Pain), both of which 
showed more outspoken improvement in the present 
analysis.
Whereas the main analysis comprised patients with 
evaluable data for each follow-up, we performed sensitivity 
analyses of the 0–24-month improvements of HFAQ and 
LBPRS, replacing missing values with the last observation 
carried forward (Table 2). Compared to the main analysis, 
the average improvement of HFAQ was increased by 6% 
(11.04→11.71 points) while the improvement of LBPRS 
was decreased by 9% (8.71→7.92 points).
Other outcomes
One adverse reaction to AM treatment was documented (mild 
headache from eurythmy therapy, which was not stopped due 
to this reaction). Other reported adverse reactions referred 
to acupuncture (n = 1 patient), psychotherapy (n = 1), and 
non-AM medications (n = 12).
Two serious adverse events occurred: A 61-year-old 
woman hospitalized for severe depression died from an 
accident, possibly suicide. A 42-year-old woman was 
acutely hospitalized due to an exacerbation of a coexisting 
Löfgren syndrome, from which she recovered completely. 
These events occurred 23 months and six months after study 
enrolment, respectively, and were not related to any therapy 
or medication.
Discussion
Main findings
This is a two-year follow-up analysis of the first study of 
comprehensive AM treatment for LBP in primary care. 
We studied 75 outpatients starting AM treatment (mainly 
eurythmy therapy, rhythmical massage therapy, and 
medications) for chronic LBP. A previous 12-month analysis 
had shown improvements in pain, back function, and quality 
of life under AM treatment, comparable to or more extensive 
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than improvements in patients receiving conventional care.10 
The present follow-up analysis of AM patients confirmed 
these improvements in a larger sample and showed that the 
improvements were maintained at two-year follow-up. Most 
improvements were clinically relevant (large 0–24-month 
effect size for SF-36 Bodily Pain, medium effect sizes for 
seven out of 13 remaining clinical outcomes). Comparing 
the pre-study year to the first and the second year after study 
enrolment, the use of non-AM adjunctive therapies and of 
health services did not increase. Adverse reactions to AM 
treatment occurred in only one patient.
strengths and limitations
Strengths of this study include a detailed assessment of the 
therapy setting and therapy-related factors, a standardized 
assessment of back pain and function as well as quality of 
life, a long follow-up period, and a high representativeness: 
10% of all AM-certified physicians in Germany participated, 
the participating AM physicians and therapists resembled 
all eligible physicians and therapists with respect to 
sociodemographic characteristics, and 93% of screened and 
eligible patients were enrolled. These features suggest that the 
study to a high degree mirrors contemporary AM practice.
The main research question of the present analysis concerned 
the magnitude of long-term improvements. A limitation in this 
respect is the increasing long-term dropout rate (20%, 28%, 
and 33% after 12, 18, and 24 months, respectively). Dropouts 
did not differ from evaluable patients regarding baseline char-
acteristics (except dropouts were younger, which would not be 
associated with a worse outcome23), and in a telephone survey 
of a different subset of patients from the AMOS project, the 
proportion of patients with clinical deterioration at 24-month 
follow-up was comparable in dropouts and respondents. In a 
sensitivity analysis of the primary outcomes, replacing missing 
values in dropouts with their last observation carried forward, 
improvements were reduced by maximum 9%. A general 
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explanation for late dropout is the tendency of study subjects 
to fail to respond to repeated questionnaires. Nevertheless, 
since LBP is a recurring disorder, we cannot exclude that 
some late dropouts might have relapsed. A general limitation 
of the analysis is the modest sample size.
This analysis assessed AM as a whole system.12 
Supplementary subgroup analysis was possible for 
patients referred to eurythmy therapy and showed similar 
improvements in this group, while the sample size of the 
other therapy modality subgroups (medical, art, rhythmical 
massage) did not allow for subgroup analysis.
Since the study had a long recruitment period, the study 
physicians were not able to participate throughout the 
period and to screen and enroll all eligible patients (criteria: 
see Methods section). For a different subset of patients 
from the AMOS project (patients referred to AM therapies 
and enrolled before April 1st, 2001), it was estimated that 
physicians enrolled every fourth eligible patient.24 This 
selection could bias results if physicians were able to predict 
therapy response and if they preferentially screened and 
enrolled such patients for whom they expected a particularly 
favorable outcome. In this case one would expect the degree 
of selection (the proportion of eligible vs. enrolled patients) 
to correlate positively with clinical outcomes. That was 
not the case, the correlation was almost zero (-0.04). This 
analysis24 does not suggest that physicians’ screening of 
eligible patients was affected by selection bias.
Because 13 clinical outcomes were analyzed with a total 
of 17 comparisons at 24-month follow-up (Table 2), the 
issue of multiple hypothesis-testing arises.19 However, all 
17 comparisons showed significant improvements and 11 
comparisons had p-values 0.001.
Table 2 clinical outcomes 0–24 months
Analysis/Outcome (range) N 0 months 24 months 0–6 month difference SRM
Mean (SD) Mean (SD) Mean (95% CI)a P-value
Main analysis: patients with evaluable 
data at 0 and 24 months
HFAQ (0–100)
• All therapies 46 61.63 (19.77) 72.68 (21.45) 11.04 (5.52–16.57) 0.001 0.59
•  eurythmy therapy 31 61.62 (19.62) 71.24 (21.04) 9.61 (3.25–15.98) 0.004 0.55
LBPRs (0–100)
• All therapies 47 34.99 (15.10) 26.28 (16.91) 8.71 (4.41–13.01) 0.001 0.59
•  eurythmy therapy 32 33.93 (14.60) 25.52 (16.93) 8.41 (3.57–13.24) 0.001 0.66
symptom score (0–10) 49 5.79 (2.05) 3.76 (2.12) 2.04 (1.30–2.77) 0.001 0.79
ces-D (0–60) 41 20.14 (9.93) 15.54 (11.09) 4.60 (1.37–7.84) 0.006 0.45
sF-36 Physical component 46 35.73 (7.57) 41.72 (10.31) 5.99 (2.88–9.11) 0.001 0.57
sF-36 Mental component 46 42.27 (10.03) 46.22 (10.89) 3.95 (1.13–6.78) 0.007 0.42
sF-36 scales (0–100)
•  Physical Function 48 63.65 (20.10) 72.06 (23.47) 8.41 (1.68–15.15) 0.015 0.36
•  Role Physical 49 30.61 (34.71) 56.63 (40.11) 26.02 (14.12–37.93) 0.001 0.63
•  Role emotional 47 53.90 (42.02) 72.34 (38.27) 18.44 (6.57–30.31) 0.003 0.46
•  social Functioning 49 64.29 (23.52) 74.74 (22.75) 10.46 (4.49–16.43) 0.001 0.50
•  Mental Health 49 56.16 (16.75) 63.33 (18.59) 7.16 (2.19–12.13) 0.006 0.41
•  Bodily Pain 49 32.78 (17.45) 53.94 (24.74) 21.16 (13.83–28.49) 0.001 0.83
•    Vitality 49 36.26 (14.11) 48.16 (18.13) 11.91 (7.59–16.22) 0.001 0.79
•  general Health 49 49.38 (19.20) 55.34 (21.77) 5.96 (1.41–10.50) 0.011 0.38
Sensitivity analysis: Last value 
carried forward
HFAQ 73 62.13 (19.64) 73.83 (19.95) 11.71 (7.61–15.80) 0.001 0.67
LBPRs 72 36.61 (16.40) 28.69 (18.52) 7.92 (4.71–11.13) 0.001 0.63
Note: aPositive differences indicate improvement.
Abbreviations: CES-D, Center for Epidemiological Studies Depression Scale, German version; CI, confidence interval; HFAQ, Hanover Functional Ability Questionnaire; LBPRS, Low 
Back Pain Rating scale Pain score; sD, standard deviation; sRM, standardized response mean effect size (minimal: 0.20, small: 0.20–0.49, medium: 0.50–0.79, large: 0.80).Journal of Pain Research 2009:2 84
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Agreement with existing literature
Previous studies have found beneficial effects of AM 
therapies for nonspecific LBP (AM rhythmic embrocation 
therapy8) as well as discogenic LBP (subcutaneous 
injections of AM medications7 comprehensive inpatient 
AM therapy.9) The last study also found reduced use of 
nonsteroid anti-inflammatory drugs and muscle relaxants 
and earlier return to work after AM therapy, compared to 
conventional inpatient treatment.9 In accordance with these 
studies, conducted in specialized settings, we have observed 
clinically relevant improvement in symptoms, back function, 
and quality of life following AM therapies in a primary 
care setting.10 The present analysis confirms these findings 
in a larger sample and shows that improvements can be 
maintained for up to two years.
study implications
In this study, AM therapies for chronic LBP were associated 
with substantial long-term improvement of symptoms, back 
function, and of quality of life without increase in the use of 
adjunctive therapies or health services. The improvement in 
back function, assessed by HFAQ, was at least of the same 
order of magnitude as corresponding improvements in other 
German LBP cohorts receiving other treatments and followed 
up for 12–24 months.25–28
Some patients will not profit from standard therapies 
for LBP. Other patients discontinue standard therapies due 
to adverse reactions or reject them because therapies are 
passive (eg, drugs) or too mechanical-repetitive (exercise 
physiotherapy). In this context, AM seems a promising treat-
ment option for chronic LBP. It should be noted, however, 
that eurythmy therapy, which was used by most patients 
in this study, entails daily exercises of artistic movements 
over a period of several months, which requires sustained 
motivation.
Conclusions
In this follow-up analysis of patients receiving AM therapies 
for chronic LBP, improvements of symptoms, back function, 
and quality of life were found in a larger sample size and 
were maintained at two-year follow up, suggesting that larger 
multicenter rigorous studies may be worthwhile.
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